Browse
You are looking at 21 - 30 of 1,463 items for
Search for other papers by I M.a.a. van Roessel in
Google Scholar
PubMed
Search for other papers by Je Gorter in
Google Scholar
PubMed
Search for other papers by Boudewijn Bakker in
Google Scholar
PubMed
Search for other papers by Mm van den Heuvel-Eibrink in
Google Scholar
PubMed
Search for other papers by M H Lequin in
Google Scholar
PubMed
Search for other papers by J van der Lugt in
Google Scholar
PubMed
Search for other papers by L Meijer in
Google Scholar
PubMed
Search for other papers by A.y.n. Schouten-van Meeteren in
Google Scholar
PubMed
Search for other papers by H M van Santen in
Google Scholar
PubMed
Objective: Children with a supratentorial midline low grade glioma (LGG) may be at risk for impaired bone health due to hypothalamic-pituitary dysfunction, obesity, exposure to multiple treatment modalities, and/or decreased mobility. The presence of impaired bone health and/or its severity in this population has been understudied. We aimed to identify the prevalence and risk factors for bone problems in children with supratentorial midline LGG.
Design and Methods: A retrospective study was performed in children with supratentorial midline (suprasellar or thalamic) LGG between 1-1-2003 and 1-1-2022, visiting the Princess Máxima Center for Pediatric Oncology. Impaired bone health was defined as presence of vertebral fractures and/or very low bone mineral density (BMD).
Results: In total, 161 children were included, with a median age at tumor diagnosis of 4.7 years (range 0.1 – 17.9) and a median follow-up of 6.1 years (range 0.1 – 19.9). Five patients (3.1 %) had vertebral fractures. In 99 patients BMD was assessed either by Dual Energy X ray Absorptiometry (n=12) or Bone Health Index (n=95); 34 patients (34.3%) had a low BMD (≤ -2.0). Impaired visual capacity was associated with bone problems in multivariable analysis (OR 6.63, 95% CI 1.83 – 24.00, p = 0.004).
Conclusions: In this retrospective evaluation, decreased BMD was prevalent in 34.3% of children with supratentorial midline LGG. For the risk to develop bone problems visual capacity seems highly relevant. Surveillance of bone health must be an aspect for awareness in the care and follow-up of children with a supratentorial midline LGG.
Search for other papers by Dafydd Aled Rees in
Google Scholar
PubMed
Search for other papers by Deborah P Merke in
Google Scholar
PubMed
Search for other papers by Wiebke Arlt in
Google Scholar
PubMed
Search for other papers by Aude Brac De La Perriere in
Google Scholar
PubMed
Search for other papers by Angelica Linden Hirschberg in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John Newell-Price in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Philippe A Touraine in
Google Scholar
PubMed
Search for other papers by Alex Lewis in
Google Scholar
PubMed
Search for other papers by John Porter in
Google Scholar
PubMed
Search for other papers by Helen Coope in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Background
Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone.
Design
Six-month open-label randomised phase 3 study and interim analysis of a single-arm extension study was the design of the study.
Methods
The method of the study was hydrocortisone dose equivalent and 09:00-h 17-hydroxyprogesterone (17OHP) from 48 patients taking prednis(ol)one at baseline.
Results
At baseline, the median hydrocortisone dose equivalent was 30 mg/day and 17OHP was < 36 nmol/L (3× upper limit of normal) in 56% of patients. Patients were randomised to continue prednis(ol)one or switch to modified-release hydrocortisone capsule (MRHC) at the same hydrocortisone-equivalent dose. At 4 weeks, 94% on MRHC and 71% on prednis(ol)one had 17OHP < 36 nmol/L. At 18 months in the extension study of MRHC, the median MRHC dose was 20 mg/day and 82% had 17OHP < 36 nmol/L. The per cent of patients with 17OHP < 36 nmol/L on a hydrocortisone dose equivalent ≤ 25 mg/day was greater at 18 months in the extension study on MRHC than while on prednis(ol)one at baseline: 57% vs 27%, P = 0.04. In the randomised study, no patients had an adrenal crisis on MRHC and one on prednisolone. In the extension study (221 patient years), there were 12 adrenal crises in 5 patients (5.4/100 patient years).
Conclusion
MRHC reduces 17OHP at 09:00 h compared to prednis(ol)one and the dose of MRHC can be down-titrated over time in the majority of patients.
Search for other papers by Theodoros Karampitsakos in
Google Scholar
PubMed
Search for other papers by Fotini Kanouta in
Google Scholar
PubMed
Search for other papers by Christos Chatzakis in
Google Scholar
PubMed
Search for other papers by Vassilios Bakoulas in
Google Scholar
PubMed
Search for other papers by Alexandros Gryparis in
Google Scholar
PubMed
Search for other papers by Petros Drakakis in
Google Scholar
PubMed
Search for other papers by Djuro Macut in
Google Scholar
PubMed
Search for other papers by George Mastorakos in
Google Scholar
PubMed
Introduction: To investigate whether synthetic (s) glucocorticoids (GCs) administrated between 24th and 34th gestational weeks in pre-term labor, might precipitate labor, studies upon sGCs administration were reviewed. Physiology of endogenous glucocorticoids-related increase in fetal-maternal circulation and its association with labor, followed by a scoping review with studies on exogenous sGCs administrated for fetal lung maturation and the timing of labor were included.
Material and methods: Methodology of systematic reviews was followed. MEDLINE, Cochrane library and Google Scholar databases were searched till October 2023, for original studies investigating administration of sGCs in pregnancies risking pre-term labor. Duplicates were removed and 1867 abstracts were excluded as irrelevant. Six controlled and four non-controlled studies were included. The index group consisted of 6001 subjects and 7691 controls in the former, while in the latter the index group consisted of 2069 subjects.
Results: In three out of the six controlled studies, gestational age at labor was significantly lower in sGCs-treated women than in controls, while in three studies gestational age at labor was lower in sGCs-treated women than in controls with a trend of statistical significance . In one study, gestational age at labor was significantly lower in controls than in sGCs-treated women. In the non-controlled studies, the majority of women delivered less than one week from the day of sGCs administration.
Conclusions: In this scoping review, studies lack homogeneity. However, in the controlled studies, a pattern of earlier labor emerges among sGCs-treated pregnant women. The use of multiple courses of ante-natal sGCs appears to be associated to precipitated labor. Their use should be carefully weighed. Carefully designed trials should examine this still open scientific query.
Search for other papers by Alessandro Barbato in
Google Scholar
PubMed
Search for other papers by Giulia Gori in
Google Scholar
PubMed
Search for other papers by Michele Sacchini in
Google Scholar
PubMed
Search for other papers by Francesca Pochiero in
Google Scholar
PubMed
Search for other papers by Sara Bargiacchi in
Google Scholar
PubMed
Search for other papers by Giovanna Traficante in
Google Scholar
PubMed
Search for other papers by Viviana Palazzo in
Google Scholar
PubMed
Search for other papers by Lucia Tiberi in
Google Scholar
PubMed
Search for other papers by Claudia Bianchini in
Google Scholar
PubMed
Search for other papers by Davide Mei in
Google Scholar
PubMed
Search for other papers by Elena Parrini in
Google Scholar
PubMed
Search for other papers by Tiziana Pisano in
Google Scholar
PubMed
Search for other papers by Elena Procopio in
Google Scholar
PubMed
Search for other papers by Renzo Guerrini in
Google Scholar
PubMed
Search for other papers by Angela Peron in
Google Scholar
PubMed
Search for other papers by Stefano Stagi in
Google Scholar
PubMed
Context: Cytochrome C oxidase (COX) is the fourth component of the respiratory chain and is located within the internal membrane of mitochondria. COX deficiency causes an inherited mitochondrial disease with significant genetic and phenotypic heterogeneity. Four clinical subtypes have been identified, each with distinct phenotypes and genetic variants.
Mitochondrial complex IV deficiency nuclear type 4 (MC4DN4) is a form of COX deficiency associated with pathogenetic variants in the SCO1 gene.
Case description: We describe three patients with MC4DN4 with developmental and epileptic encephalopathy (DEE), hypopituitarism and SCO1 pathogenic variants. These patients’ phenotypes considerably differ from previously reported MC4DN4 phenotypes as they associated DEE with progressive hypopituitarism and survival beyond the first months after birth. Pituitary deficiency in these patients progressively worsened and mainly involved growth hormone secretion and thyroid function.
Conclusions: Our findings expand knowledge of phenotypic variability in MC4DN4 and suggests that SCO1 is a candidate gene for genetic hypopituitarism and DEE.
Search for other papers by Clara Lundetoft Clausen in
Google Scholar
PubMed
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
Search for other papers by Niels Erik Skakkebæk in
Google Scholar
PubMed
Search for other papers by Hanne Frederiksen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Thomas Benfield in
Google Scholar
PubMed
In the context of severe coronavirus disease 2019 (COVID-19) illness, we examined endogenous glucocorticoid concentrations, steroidogenic enzyme activity, and their correlation with inflammation and patient outcomes. This observational study included 125 hospitalized COVID-19 patients and 101 healthy individuals as a reference group. We utilized LC-MS to assess serum concentrations of 11-deoxycortisol, cortisol, and cortisone, as well as activities of steroidogenic enzymes (11β-hydroxylase and 11β-hydroxysteroid-dehydrogenase type 1). Cox proportional hazards regression analysis and competing risk analysis were employed to analyze associations between glucocorticoid concentrations and outcomes, adjusting for relevant factors. In patients with COVID-19, cortisol concentrations were higher and cortisone concentrations were lower compared to the reference group, while 11-deoxycortisol concentrations were similar. Steroidogenic enzyme activity favored cortisol production. Correlations between glucocorticoid concentrations and inflammatory markers were low. A doubling in concentrations cortisol, was associated with increased 90-day mortality and mechanical ventilation (HR: 2.40 95% CI: (1.03–5.59) , P = 0.042 and HR: 3.83 (1.19–12.31), P = 0.024). A doubling in concentrations of 11-deoxycortisol was also associated to mortality (HR: 1.32 (1.05–1.67), P = 0.018), whereas concentrations of cortisone were associated with mechanical ventilation (HR: 5.09 (1.49–17.40), P = 0.009). In conclusion, serum concentrations of glucocorticoid metabolites were altered in patients hospitalized with severe COVID-19, and steroidogenic enzyme activity resulting in the conversion of cortisone to biologically active cortisol was preserved, thus not favoring critical-illness-related corticosteroid insufficiency at the enzymatic level. Glucocorticoid release did not counterbalance the hyperinflammatory state in patients with severe COVID-19. High serum concentrations of 11-deoxycortisol and cortisol were associated with 90-day mortality, and high serum concentrations of cortisol and cortisone were associated with mechanical ventilation.
Search for other papers by Budoor Alemadi in
Google Scholar
PubMed
Search for other papers by Fauzia Rashid in
Google Scholar
PubMed
Search for other papers by Ali S Alzahrani in
Google Scholar
PubMed
Primary hyperparathyroidism has emerged as a prevalent endocrine disorder in clinical settings, necessitating in most cases, surgical intervention for the removal of the diseased gland. This condition is characterised by overactivity of the parathyroid glands, resulting in excessive parathyroid hormone production and subsequent disturbances in calcium homeostasis. The primary mode of management is surgical treatment, relying on the accurate localisation of the pathological parathyroid gland. Precise identification is paramount to ensuring that the surgical intervention effectively targets and removes the diseased gland, alleviating the hyperfunctioning state. However, localising the gland becomes challenging, as discrepancies between the clinical manifestation of active parathyroid and radiological identification are common. Based on our current knowledge, to date, no comprehensive review has been conducted that considers all factors collectively. This comprehensive review delves into the factors contributing to false-negative 99mTc-sestamibi scans. Our research involved an exhaustive search in the PubMed database for hyperparathyroidism, with the identified literature meticulously filtered and reviewed by the authors. The results highlighted various factors, including multiple parathyroid diseases, nodular goitre, mild disease, or the presence of an ectopic gland that causes discordance. Hence, a thorough consideration of these factors is crucial during the diagnostic workup of hyperparathyroidism. Employing intraoperative PTH assays can significantly contribute to a successful cure of the disease, thereby providing a more comprehensive approach to managing this prevalent endocrine disorder.
Division of Epidemiology and Biometry, Carl von Ossietzky Universität, Oldenburg, Germany
Search for other papers by Julia Beckhaus in
Google Scholar
PubMed
Search for other papers by Maria Eveslage in
Google Scholar
PubMed
Search for other papers by Brigitte Bison in
Google Scholar
PubMed
Search for other papers by Carsten Friedrich in
Google Scholar
PubMed
Search for other papers by Hermann L Müller in
Google Scholar
PubMed
Objective
It is well known that both genetic background and lifestyle influence the development of ‘general’ obesity. However, the role of parental body mass index (BMI) on the development of obesity in long-term survivors of childhood-onset craniopharyngioma (CP) is not well understood. This study analyzed the correlation of patients’ BMI at diagnosis and last visit and parental BMI at CP diagnosis and further explored potential risk factors for obesity in CP patients.
Design
This is a registry-based retrospective cohort study.
Methods
In total,291 CP patients and their parents recruited in the German KRANIOPHARYNGEOM studies were included. Correlations between patient’s BMI SDS at CP diagnosis and last visit and parental BMI at CP diagnosis were analyzed. The associations between hypothalamic damage, maternal/paternal BMI and CP patients’ obesity at last visit were analyzed by multivariable logistic regression.
Results
At follow-up, 52% of CP patients developed obesity (BMI > 3SDS). Patient’s BMI SDS at last visit was moderately correlated with BMI-SDS at CP diagnosis (r = 0.48, 95% CI: 0.38–0.58, P < 0.001), and also with maternal BMI at diagnosis (r = 0.28, 95% CI: 0.17–0.38, P < 0.001) and paternal BMI at diagnosis (r = 0.3, 95% CI: 0.19–0.41, P < 0.001). However, the contributing role of parental BMI to the pathogenesis of obesity was small compared to the impact of hypothalamic damage.
Conclusion
We conclude that besides hypothalamic damage, parental disposition for obesity is associated with the development of obesity in patients after CP. Our results indicate that also the family situation could have an influence on the development of obesity after CP and might be a therapeutic target.
Significance statement
Survivors of childhood-onset craniopharyngioma are at risk of developing morbid obesity. So far, patients with posterior hypothalamic involvement and lesion were identified as a high risk group. With this study, the influence of parental body mass index on the risk of obesity was investigated. Patient’s body-mass-index at last visit was correlated with maternal and paternal body mass index at diagnosis. With increasing maternal or paternal body mass index, the likelihood of obesity in individuals with CP increased. Nevertheless, the parents’ weight had only a small effect on the development of patients’ obesity compared to hypothalamic damage.
Search for other papers by Hana Vítková in
Google Scholar
PubMed
Search for other papers by Kateřina Anderlová in
Google Scholar
PubMed
Search for other papers by Jan Krátký in
Google Scholar
PubMed
Search for other papers by Radovan Bílek in
Google Scholar
PubMed
Search for other papers by Drahomíra Springer in
Google Scholar
PubMed
Search for other papers by Felix Votava in
Google Scholar
PubMed
Search for other papers by Tomáš Brutvan in
Google Scholar
PubMed
Search for other papers by Adéla Krausová in
Google Scholar
PubMed
Search for other papers by Kristýna Žabková in
Google Scholar
PubMed
Search for other papers by Eliška Potluková in
Google Scholar
PubMed
Search for other papers by Jan Jiskra in
Google Scholar
PubMed
Introduction: Maternal urinary iodine concentration (UIC) and blood neonatal thyroid stimulating hormone (TSH) concentration reflect iodine status in pregnancy. As dietary measures in gestational diabetes mellitus (GDM) could affect iodine intake, our study aimed to investigate iodine supply in women with GDM compared to healthy pregnant women and to evaluate its relationship to thyroid function.
Methods: UIC and serum TSH, free thyroxine (FT4) and autoantibodies against thyroid peroxidase (TPOAb) were analysed in 195 women with GDM and 88 healthy pregnant women in the 2nd trimester. Subsequently, neonatal TSH concentrations measured 72 hours after delivery in a subgroup of 154 newborns (115 of mothers with GDM and 39 controls) from the national register were analysed.
Results: Optimal iodine intake was found only in nine women with GDM (4.6%) and 33 healthy pregnant women (37.5%) (P<0.001). Most pregnant women with GDM (88.7%) as compared to one half of controls (50%) had iodine deficiency (P<0.001). Also, hypothyroxinaemia was more prevalent in GDM compared to controls (12.3% vs 3.4%, P = 0.032). Consistently, neonatal TSH >5.0 mIU/L indicating iodine deficiency was found in 6 (5.2%) newborns of women with GDM as compared to none in controls. In the multiple logistic and linear regression models in women with GDM, hypothyroxinaemia was associated with preterm births, and a negative association of serum FT4 and HbA1c was found.
Conclusion: Iodine deficiency in pregnancy was more prevalent among women with GDM compared to healthy pregnant controls. Hypothyroxinaemia was associated with preterm births in women with GDM.
Search for other papers by Rohit Barnabas in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Anurag Ranjan Lila in
Google Scholar
PubMed
Search for other papers by Sirisha Kusuma Boddu in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Sneha Arya in
Google Scholar
PubMed
Search for other papers by Samiksha Chandrashekhar Hegishte in
Google Scholar
PubMed
Search for other papers by Manjiri Karlekar in
Google Scholar
PubMed
Search for other papers by Virendra A Patil in
Google Scholar
PubMed
Search for other papers by Vijaya Sarathi in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Background: The data on Leydig cell hypoplasia (LCH) resulting from biallelic Luteinizing hormone/chorionic gonadotropin receptor (LHCGR) inactivating variants is limited to case series.
Methods: We aim to describe our patients and perform systematic review of the patients with LHCGR inactivating variants in the literature. Detailed phenotype and genotype data of 3 patients from our centre and 85 (46,XY: 67; 46,XX: 18) patients from 59 families with LHCGR-inactivating variants from literature were described.
Results: Three 46,XY patients(age 6-18 years) from our centre, with two reared as females, had two novel variants in LHCGR. Systematic review (including our patients) revealed 72 variants in 88 patients. 46,XY patients (n=70, 56 raised as females) presented with pubertal delay (n=41) or atypical genitalia(n=17). Sinnecker score ≥3 (suggesting antenatal hCG inaction) was seen in 80% (56/70), and hCG-stimulated testosterone was low (<1.1 ng/ml) in 77.4% (24/31), whereas puberty/postpubertal age, high LH (97.6%, 41/42) and low (<1.0 ng/ml) basal testosterone (94.9%, 37/39) was observed in most. FSH was elevated in 21/51 of these patients. Variants with <10% receptor function were exclusively seen in cohorts with Sinnecker 4/5 (10/15 vs. 0/5, p=0.033). 46,XX patients (n=18) presented with oligo/amenorrhea and/or anovulatory infertility and had polycystic ovaries (7/9) with median LH of 10 IU/L (1.2-38).
Conclusion: In summary, this study comprehensively characterizes LHCGR variants, revealing genotype-phenotype correlations and informing clinical management of LCH. In 46,XY LCH patients, pubertal LH inaction is uniform with variable severity of antenatal hCG inaction. Few mutant LHCGR have differential action for LH and hCG.
Search for other papers by Lei Gao in
Google Scholar
PubMed
Search for other papers by Wenxia Cui in
Google Scholar
PubMed
Search for other papers by Dinghuang Mu in
Google Scholar
PubMed
Search for other papers by Shaoping Li in
Google Scholar
PubMed
Search for other papers by Nan Li in
Google Scholar
PubMed
Search for other papers by Weihong Zhou in
Google Scholar
PubMed
Search for other papers by Yun Hu in
Google Scholar
PubMed
Objective
To create a nomogram-based model to estimate the Chinese population's 5-year risk of metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods
We randomly divided 7582 participants into two groups in a 7:3 ratio: one group was assigned to work with the training set, which consisted of 5307 cases, and the other group was assigned to validate the model using 2275 cases. The least absolute shrinkage and selection operator model was employed to ascertain the variables with the highest correlation among all potential variables. A logistic model was constructed by incorporating these selected variables, which were subsequently visualized using a nomogram. The discriminatory ability, calibration, and clinical utility of the model were assessed using the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).
Results
During the 5-year follow-up, 1034 (13.64%) total participants were newly diagnosed with MASLD. Using eight variables (gender, body mass index, waist, hemoglobin, alanine aminotransferase, uric acid, triglycerides, and high-density lipoprotein), we built a 5-year MASLD risk prediction model. The nomogram showed an area under the ROC of 0.795 (95% CI: 0.779–0.811) in the training set and 0.785 (95% CI: 0.760–0.810) in the validation set. The calibration curves revealed a 5-year period of agreement between the observed and predicted MASLD risks. DCA curves illustrated the practicality of this nomogram over threshold probability profiles ranging from 5% to 50%.
Conclusion
We created and tested a nomogram to forecast the risk of MASLD prevalence over the next 5 years.
